Atreca Past Earnings Performance
Past criteria checks 0/6
Atreca's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-14.6%
Earnings growth rate
51.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -908.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Jul 23
Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?
Dec 08Atreca GAAP EPS of -$0.72 misses by $0.02
Aug 08Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Jun 18Atreca: Biotech With Promise Based On First Candidate ATRC-101
Apr 22Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?
Mar 05Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case
Jan 25Atreca: Safety Data Brought Down Stock
Sep 10Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?
Sep 02We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth
May 14Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares
Jan 29We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth
Dec 07
Atreca EPS misses by $0.06
Nov 12Revenue & Expenses BreakdownBeta
How Atreca makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -98 | 36 | 45 |
| 30 Jun 23 | 0 | -85 | 38 | 51 |
| 31 Mar 23 | 0 | -93 | 39 | 58 |
| 31 Dec 22 | 0 | -97 | 39 | 62 |
| 30 Sep 22 | 0 | -105 | 40 | 68 |
| 30 Jun 22 | 0 | -110 | 41 | 70 |
| 31 Mar 22 | 0 | -108 | 43 | 67 |
| 31 Dec 21 | 0 | -109 | 43 | 67 |
| 30 Sep 21 | 0 | -103 | 42 | 61 |
| 30 Jun 21 | 0 | -98 | 42 | 59 |
| 31 Mar 21 | 0 | -92 | 38 | 55 |
| 31 Dec 20 | 0 | -86 | 37 | 52 |
| 30 Sep 20 | 0 | -83 | 37 | 50 |
| 30 Jun 20 | 0 | -76 | 33 | 48 |
| 31 Mar 20 | 0 | -74 | 29 | 50 |
| 31 Dec 19 | 0 | -67 | 24 | 49 |
| 30 Sep 19 | 0 | -59 | 17 | 48 |
| 30 Jun 19 | 0 | -53 | 13 | 43 |
| 31 Mar 19 | 0 | -44 | 11 | 35 |
| 31 Dec 18 | 0 | -38 | 9 | 31 |
Quality Earnings: BCEL is currently unprofitable.
Growing Profit Margin: BCEL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BCEL is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BCEL has a negative Return on Equity (-908.6%), as it is currently unprofitable.